Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL-27/IL-27A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-27 Heterodimer (p28/IL-27A & EBI3) Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View IL-27 Products |
| Antigen Subunit | IL-27A (p28) Recombinant Monomer For subunit-specific epitope mapping. HEK293 expressed. |
View IL-27A Products |
| Gene Delivery | IL-27RA Promise-ORF / Lentivirus Full-length ORF for stable receptor-expressing cell lines. |
View IL-27RA Products |
| Benchmark Ab | Anti-IL-27 Recombinant Antibody (SRF388 Sequence) Recombinant positive control for ligand-receptor blocking. |
View IL-27 Products |
| Validator | IL-27A siRNA Set For knockdown verification in functional cell assays. |
View IL-27A Products |
| Related Target A | IL-27RA (WSX-1) The specific alpha subunit of the IL-27 receptor complex. Essential for binding assays. |
View IL-27RA Products |
| Related Target B | gp130 (IL6ST) The signal-transducing beta subunit shared with IL-6. Crucial for selectivity screening. |
View gp130 Products |
| Related Target C | EBI3 The heterodimeric partner of IL-27A. Important for off-target screening against IL-35. |
View EBI3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer Stability & Conformation | Co-expressed IL-27A and EBI3 subunits forming stable heterodimers, verified by SEC-HPLC. |
| Subfamily Cross-reactivity (IL-12/IL-35) | Recombinant EBI3 and related subunit panels strictly verified by mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies (SRF388 biosimilar) included for assay validation. |
| False Positives in Knockdown | Sequence-verified siRNA pool designed for highly specific gene silencing. |
Live IL-27 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-27 therapeutics is intensifying, with major players shifting focus from traditional systemic cytokine therapies to monoclonal antibodies blocking IL-27-mediated immunosuppression. As first-generation therapies reach the clinic, the next wave of R&D is targeting the reversal of immune exclusion in cold tumors, particularly in combination with anti-PD-1/PD-L1 agents.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking) | Coherus BioSciences (SRF388) | HCC, NSCLC, Solid Tumors | Ligand-receptor blocking assays (Need stable heterodimeric IL-27 and IL-27RA) |
| Bispecific / Fusion Protein | Academic & Biotech Consortia | Autoimmune Diseases, Oncology | Dual-targeting validation (Need cross-species reactive IL-27 subunits) |
| mRNA / Gene Therapy | Preclinical stage developers | Local tumor microenvironment modulation | In vitro validation of expression (Need stable cell line construction via Lentivirus) |